Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
2-5-1|Rn-CR-WL 0,S52 G1C10/83|Sequence:1, Age:77,Type:chrysotyl,Quantity:20,Unit:milligrams,Application:Injection, subcutaneously, Remarks:subcut. for 1m|105 (0 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|No information on individuals available for this study
2-5-2|Rn-CH-WL 1000,28-7 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study 
|2-5-2-1|2|527|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-2|2|566|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-3|2|600|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-4|2|618|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-5|2|644|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-6|2|651|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-7|2|718|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-5-2|Rn-CH-WL 1000,28-7 4/77|1| 77|Rn-222 gas|1000|working level months|Inhalation| inhaled over 1.5 m at 1000 WL|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-8|2|721|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|2| 148|chrysotyl|2|milligrams|Injection intrapleural| intrapleural cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-1|2|527|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|2| 148|chrysotyl|2|milligrams|Injection intrapleural| intrapleural cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-2|2|566|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|2| 148|chrysotyl|2|milligrams|Injection intrapleural| intrapleural cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-3|2|600|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|2| 148|chrysotyl|2|milligrams|Injection intrapleural| intrapleural cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-4|2|618|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|2| 148|chrysotyl|2|milligrams|Injection intrapleural| intrapleural cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-5|2|644|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|2| 148|chrysotyl|2|milligrams|Injection intrapleural| intrapleural cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-6|2|651|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-2|Rn-CH-WL 1000,28-7 4/77|2| 148|chrysotyl|2|milligrams|Injection intrapleural| intrapleural cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-7|2|718|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-5-2|Rn-CH-WL 1000,28-7 4/77|2| 148|chrysotyl|2|milligrams|Injection intrapleural| intrapleural cont.|8 (8 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-2-8|2|721|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-3|Rn-CRs-WL 1600,S52 G2RC 10/83|Sequence:1, Age:77,Type:Rn-222 gas,Quantity:1600,Unit:working level months,Application:Inhalation, Remarks:inhaled over 4 m at 3000 WL|109 (0 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|No information on individuals available for this study
2-5-3|Rn-CRs-WL 1600,S52 G2RC 10/83|Sequence:2, Age:77,Type:chrysotyl,Quantity:20,Unit:milligrams,Application:Injection, subcutaneously, Remarks:subcutan. for 1 m|109 (0 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|No information on individuals available for this study
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-1|4|1|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-2|4|11|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-3|4|181|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-4|4|189|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-5|4|241|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-6|4|317|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-7|4|407|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-8|4|416|Hyperplastic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-9|4|432|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-10|4|457|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-11|4|485|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-12|4|509|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-13|4|615|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-14|4|634|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-15|4|647|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-16|4|685|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-17|4|713|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-18|4|720|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-1|4|1|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-2|4|11|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-3|4|181|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-4|4|189|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-5|4|241|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-6|4|317|Other deterministic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-7|4|407|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-8|4|416|Hyperplastic changes|Lower respiratory system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-9|4|432|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-10|4|457|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-11|4|485|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-12|4|509|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-13|4|615|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-14|4|634|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-15|4|647|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-16|4|685|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-17|4|713|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-4|Rn-CHs-WL 1600,55 4/84|2| 377|chrysotyl|10|milligrams|Inhalation| inhaled Chrysotile sonified|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-4-18|4|720|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-1|5|384|Other deterministic changes|Lower respiratory system|n/a|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-2|5|608|Other deterministic changes|Whole body|n/a|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-3|5|618|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 408 - soft tissue fibrosarcoma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-4|5|626|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-5|5|667|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-6|5|741|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-7|5|742|Hyperplastic changes|Lower respiratory system|n/a|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-8|5|747|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-9|5|765|Hyperplastic changes|Lower respiratory system|n/a|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-10|5|766|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-1|5|384|Other deterministic changes|Lower respiratory system|n/a|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-2|5|608|Other deterministic changes|Whole body|n/a|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-3|5|618|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 408 - soft tissue fibrosarcoma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-4|5|626|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-5|5|667|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-6|5|741|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-7|5|742|Hyperplastic changes|Lower respiratory system|n/a|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-8|5|747|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-9|5|765|Hyperplastic changes|Lower respiratory system|n/a|
2-5-5|Rn-CH-WL 2240,IR1 537-1 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-5-10|5|766|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-1|6|611|Other deterministic changes|Whole body|n/a|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-2|6|643|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-3|6|647|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-4|6|667|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-5|6|671|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-6|6|678|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-7|6|704|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-8|6|710|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-9|6|797|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-10|6|798|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-1|6|611|Other deterministic changes|Whole body|n/a|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-2|6|643|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-3|6|647|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-4|6|667|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-5|6|671|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-6|6|678|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-7|6|704|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-8|6|710|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-9|6|797|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-6|Rn-CHld-WL 2240,37-2 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-6-10|6|798|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-1|7|233|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-2|7|443|Other deterministic changes|Whole body|n/a|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-3|7|534|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity| metastatic,MPATH: 365 - mesothelioma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-4|7|548|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-5|7|685|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-6|7|688|Hyperplastic changes|Lower respiratory system|n/a|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-7|7|699|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-8|7|734|Neoplasia malignant|Lower respiratory system|n/a|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-9|7|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-10|7|744|Neoplasia malignant|Lower respiratory system|n/a|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-1|7|233|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-2|7|443|Other deterministic changes|Whole body|n/a|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-3|7|534|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity| metastatic,MPATH: 365 - mesothelioma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-4|7|548|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-5|7|685|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-6|7|688|Hyperplastic changes|Lower respiratory system|n/a|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-7|7|699|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-8|7|734|Neoplasia malignant|Lower respiratory system|n/a|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-9|7|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-7|Rn-CHlo-WL 2240,37-3 4/79|2| 165|chrysotyl|2|milligrams|Injection intrapleural| intrapleural Chrysotile lix.AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-7-10|7|744|Neoplasia malignant|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-1|8|519|Neoplasia benign|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-2|8|533|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-3|8|604|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-4|8|614|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-5|8|621|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-6|8|642|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-7|8|649|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-8|8|659|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-9|8|674|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-10|8|687|Neoplasia malignant|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-11|8|702|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-12|8|718|Hyperplastic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-13|8|737|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-14|8|801|Neoplasia systemic|Haematolymphatic system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-15|8|814|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-16|8|818|Hyperplastic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-17|8|822|Neoplasia benign|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-18|8|856|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-19|8|903|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1200 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-20|8|931|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-1|8|519|Neoplasia benign|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-2|8|533|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-3|8|604|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-4|8|614|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-5|8|621|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-6|8|642|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-7|8|649|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-8|8|659|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-9|8|674|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-10|8|687|Neoplasia malignant|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-11|8|702|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-12|8|718|Hyperplastic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-13|8|737|Other deterministic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-14|8|801|Neoplasia systemic|Haematolymphatic system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-15|8|814|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-16|8|818|Hyperplastic changes|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-17|8|822|Neoplasia benign|Lower respiratory system|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-18|8|856|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-19|8|903|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-5-8|Rn-AT-WL 2100,IR1 541-1,2 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-8-20|8|931|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-1|9|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-2|9|800|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-3|9|824|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-4|9|828|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-5|9|848|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-6|9|868|Other deterministic changes|Lower respiratory system|n/a|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-7|9|911|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 255 - adenoacanthoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-8|9|911|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-9|9|931|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-10|9|934|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-1|9|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-2|9|800|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-3|9|824|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-4|9|828|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-5|9|848|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-6|9|868|Other deterministic changes|Lower respiratory system|n/a|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-7|9|911|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 255 - adenoacanthoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-8|9|911|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-9|9|931|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-9|Rn-ATa-WL 2100,41-3 10/79|2| 207|attapulgite|2|milligrams|Injection intrapleural| intrapleural Attapulquite AC|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-9-10|9|934|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-1|10|660|Other deterministic changes|Lower respiratory system|n/a|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-2|10|674|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-3|10|702|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-4|10|723|Other deterministic changes|Lower respiratory system|n/a|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-5|10|731|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-6|10|758|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-7|10|779|Other deterministic changes|Lower respiratory system|n/a|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-8|10|823|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-9|10|889|Neoplasia malignant|Lower respiratory system|n/a|
2-5-10|Rn-MU-WL 2100,41-4 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-10|10|918|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-1|10|660|Other deterministic changes|Lower respiratory system|n/a|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-2|10|674|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-3|10|702|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system| benign,MPATH: 551 - sarcoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-4|10|723|Other deterministic changes|Lower respiratory system|n/a|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-5|10|731|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-6|10|758|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-7|10|779|Other deterministic changes|Lower respiratory system|n/a|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-8|10|823|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-9|10|889|Neoplasia malignant|Lower respiratory system|n/a|
2-5-10|Rn-MU-WL 2100,41-4 10/79|2| 207|mucipulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-10-10|10|918|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-1|11|345|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-2|11|519|Other deterministic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-3|11|575|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-4|11|593|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-5|11|603|Other deterministic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-6|11|666|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-7|11|681|Other deterministic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-8|11|704|Other deterministic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-9|11|738|Hyperplastic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|1| 77|Rn-222 gas|2100|working level months|Inhalation| inhaled over 3 m at 1050 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-10|11|894|Hyperplastic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-1|11|345|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-2|11|519|Other deterministic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-3|11|575|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-4|11|593|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-5|11|603|Other deterministic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-6|11|666|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-7|11|681|Other deterministic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-8|11|704|Other deterministic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-9|11|738|Hyperplastic changes|Lower respiratory system|n/a|
2-5-11|Rn-GA-WL 2100,41-5 10/79|2| 207|gastropulgite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-11-10|11|894|Hyperplastic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-1|12|1|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-2|12|11|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-3|12|181|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-4|12|189|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-5|12|241|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-6|12|317|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-7|12|407|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-8|12|416|Hyperplastic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-9|12|432|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-10|12|457|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-11|12|485|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-12|12|509|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-13|12|615|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-14|12|634|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-15|12|647|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-16|12|685|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-17|12|713|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-18|12|720|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-1|12|1|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-2|12|11|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-3|12|181|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-4|12|189|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-5|12|241|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-6|12|317|Other deterministic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-7|12|407|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-8|12|416|Hyperplastic changes|Lower respiratory system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-9|12|432|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-10|12|457|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-11|12|485|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-12|12|509|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-13|12|615|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-14|12|634|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-15|12|647|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-16|12|685|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-17|12|713|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-12|Rn-CR-WL 1600,55 4/84|2| 377|crocidolite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-12-18|12|720|Neoplasia malignant|Bone among musculo-skeletal system diseases| metastatic|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-1|13|440|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-2|13|471|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-3|13|678|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-4|13|696|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-5|13|712|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-6|13|733|Neoplasia malignant|Lower respiratory system|n/a|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-7|13|758|Hyperplastic changes|Lower respiratory system|n/a|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-8|13|786|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-9|13|791|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 3000 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-10|13|820|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-1|13|440|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-2|13|471|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-3|13|678|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-4|13|696|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-5|13|712|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-6|13|733|Neoplasia malignant|Lower respiratory system|n/a|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-7|13|758|Hyperplastic changes|Lower respiratory system|n/a|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-8|13|786|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-9|13|791|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-13|Rn-CR-WL 2240,37-4 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-13-10|13|820|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-1|14|681|Neoplasia malignant|Lower respiratory system|n/a|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-2|14|704|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-3|14|709|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-4|14|709|Other deterministic changes|Lower respiratory system|n/a|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-5|14|716|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-6|14|717|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-7|14|773|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-8|14|805|Hyperplastic changes|Lower respiratory system|n/a|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-9|14|843|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-10|14|843|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-1|14|681|Neoplasia malignant|Lower respiratory system|n/a|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-2|14|704|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-3|14|709|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-4|14|709|Other deterministic changes|Lower respiratory system|n/a|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-5|14|716|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-6|14|717|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-7|14|773|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-8|14|805|Hyperplastic changes|Lower respiratory system|n/a|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-9|14|843|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-14|Rn-CRl-WL 2240,37-5 4/79|2| 165|crocidolite|2|milligrams|Injection intrapleural| intrapleural Crocid.lix. AD|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-14-10|14|843|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-1|15|1|Other deterministic changes|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-2|15|244|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-3|15|309|Hyperplastic changes|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-4|15|410|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-5|15|417|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-6|15|419|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-7|15|427|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-8|15|465|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-9|15|465|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-10|15|531|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-11|15|534|Neoplasia malignant|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-12|15|557|Neoplasia malignant|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-13|15|579|Neoplasia malignant|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-14|15|587|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-15|15|594|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-16|15|600|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-17|15|601|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-18|15|667|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-1|15|1|Other deterministic changes|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-2|15|244|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-3|15|309|Hyperplastic changes|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-4|15|410|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-5|15|417|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-6|15|419|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-7|15|427|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-8|15|465|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-9|15|465|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-10|15|531|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-11|15|534|Neoplasia malignant|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-12|15|557|Neoplasia malignant|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-13|15|579|Neoplasia malignant|Lower respiratory system|n/a|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-14|15|587|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-15|15|594|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-16|15|600|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-17|15|601|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-15|Rn-AM-WL 2000,55 4/84|2| 377|amosite|10|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-15-18|15|667|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-1|16|622|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-2|16|627|Neoplasia malignant|Lower respiratory system|n/a|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-3|16|648|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-4|16|667|Other deterministic changes|Whole body|n/a|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-5|16|738|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-6|16|765|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-7|16|787|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-8|16|839|Neoplasia malignant|Lower respiratory system|n/a|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-9|16|843|Hyperplastic changes|Lower respiratory system|n/a|
2-5-16|Rn-CR-WL 2240,37-6 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-10|16|843|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-1|16|622|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-2|16|627|Neoplasia malignant|Lower respiratory system|n/a|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-3|16|648|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-4|16|667|Other deterministic changes|Whole body|n/a|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-5|16|738|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-6|16|765|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-7|16|787|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-8|16|839|Neoplasia malignant|Lower respiratory system|n/a|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-9|16|843|Hyperplastic changes|Lower respiratory system|n/a|
2-5-16|Rn-CR-WL 2240,37-6 4/79|2| 165|amosite|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-16-10|16|843|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-1|17|321|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-2|17|520|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-3|17|570|Other deterministic changes|Lower respiratory system|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-4|17|640|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-5|17|640|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-6|17|677|Hyperplastic changes|Lower respiratory system|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-7|17|712|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-8|17|723|Neoplasia malignant|Lower respiratory system|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-9|17|754|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-10|17|758|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-1|17|321|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-2|17|520|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-3|17|570|Other deterministic changes|Lower respiratory system|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-4|17|640|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-5|17|640|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-6|17|677|Hyperplastic changes|Lower respiratory system|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-7|17|712|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-8|17|723|Neoplasia malignant|Lower respiratory system|n/a|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-9|17|754|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-17|Rn-CRl-WL 2240,37-7 4/79|2| 165|amosite|2|milligrams|Injection intrapleural|  Amosite lix. AO|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-17-10|17|758|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-1|18|251|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-2|18|302|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-3|18|348|Neoplasia malignant|Bloodvessels among cardiovascular system| benign|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-4|18|426|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-5|18|440|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-6|18|453|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney| metastatic,MPATH: 551 - sarcoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-7|18|485|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-8|18|492|Neoplasia malignant|Lower respiratory system|n/a|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-9|18|544|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-10|18|548|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-11|18|548|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-12|18|566|Neoplasia systemic|Haematolymphatic system|n/a|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-13|18|634|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-14|18|650|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-15|18|677|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung| metastatic lung tumour,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-16|18|678|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-17|18|716|Neoplasia malignant|Lower respiratory system|n/a|
2-5-18|Rn-HE-WL 1600,55 4/84|1| 77|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-18|18|720|Neoplasia benign|Lower respiratory system|n/a|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-1|18|251|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-2|18|302|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-3|18|348|Neoplasia malignant|Bloodvessels among cardiovascular system| benign|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-4|18|426|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-5|18|440|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-6|18|453|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney| metastatic,MPATH: 551 - sarcoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-7|18|485|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-8|18|492|Neoplasia malignant|Lower respiratory system|n/a|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-9|18|544|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-10|18|548|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-11|18|548|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-12|18|566|Neoplasia systemic|Haematolymphatic system|n/a|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-13|18|634|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-14|18|650|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-15|18|677|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung| metastatic lung tumour,MPATH: 446 - squamous cell carcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-16|18|678|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-17|18|716|Neoplasia malignant|Lower respiratory system|n/a|
2-5-18|Rn-HE-WL 1600,55 4/84|2| 377|hematite|20|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-18-18|18|720|Neoplasia benign|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-1|19|406|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-2|19|550|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-3|19|586|Neoplasia malignant|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-4|19|595|Neoplasia malignant|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-5|19|614|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-6|19|633|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-7|19|642|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-8|19|649|Neoplasia malignant|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-9|19|656|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-10|19|664|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-11|19|678|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-12|19|700|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-13|19|703|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-14|19|712|Neoplasia malignant|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-15|19|724|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-16|19|726|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-17|19|735|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-18|19|735|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-19|19|738|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-20|19|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-21|19|746|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-22|19|748|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-23|19|754|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-24|19|852|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-25|19|852|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-1|19|406|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-2|19|550|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-3|19|586|Neoplasia malignant|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-4|19|595|Neoplasia malignant|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-5|19|614|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-6|19|633|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-7|19|642|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-8|19|649|Neoplasia malignant|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-9|19|656|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-10|19|664|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-11|19|678|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-12|19|700|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-13|19|703|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-14|19|712|Neoplasia malignant|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-15|19|724|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-16|19|726|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-17|19|735|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-18|19|735|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-19|19|738|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-20|19|745|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-21|19|746|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-22|19|748|Other deterministic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-23|19|754|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-24|19|852|Hyperplastic changes|Lower respiratory system|n/a|
2-5-19|Rn-SA-WL 1050,II30-3 1/78|2| 129|mineral dust (Salsigne)||unit code not relevant|Injection, intratracheal| mineral dust salsigne intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-19-25|19|852|Hyperplastic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-1|20|28|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-2|20|265|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-3|20|510|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-4|20|585|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-5|20|587|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-6|20|594|Hyperplastic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-7|20|602|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-8|20|605|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-9|20|613|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-10|20|622|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-11|20|628|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-12|20|643|Neoplasia malignant|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-13|20|654|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-14|20|656|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-15|20|664|Hyperplastic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-16|20|721|Hyperplastic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-17|20|738|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-18|20|743|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-19|20|745|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-20|20|761|Neoplasia malignant|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-21|20|761|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-22|20|794|Neoplasia malignant|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-23|20|794|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-24|20|818|Neoplasia malignant|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|1| 77|Rn-222 gas|1050|working level months|Inhalation| inhaled over 0.75 m at 1050 WL|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-25|20|853|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-1|20|28|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-2|20|265|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-3|20|510|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-4|20|585|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-5|20|587|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-6|20|594|Hyperplastic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-7|20|602|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-8|20|605|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-9|20|613|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-10|20|622|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-11|20|628|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-12|20|643|Neoplasia malignant|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-13|20|654|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-14|20|656|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-15|20|664|Hyperplastic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-16|20|721|Hyperplastic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-17|20|738|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-18|20|743|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-19|20|745|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-20|20|761|Neoplasia malignant|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-21|20|761|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-22|20|794|Neoplasia malignant|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-23|20|794|Other deterministic changes|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-24|20|818|Neoplasia malignant|Lower respiratory system|n/a|
2-5-20|Rn-FE-WL 1050,30-4 1/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-20-25|20|853|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-21|Rn-FE-WL 3000,31-2 2/78|1| 77|Rn-222 gas|3000|working level months|Inhalation| inhaled over 2 m at 1500 WL|4 (4 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-21-1|21|518|Other deterministic changes|Lower respiratory system|n/a|
2-5-21|Rn-FE-WL 3000,31-2 2/78|1| 77|Rn-222 gas|3000|working level months|Inhalation| inhaled over 2 m at 1500 WL|4 (4 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-21-2|21|563|Other deterministic changes|Lower respiratory system|n/a|
2-5-21|Rn-FE-WL 3000,31-2 2/78|1| 77|Rn-222 gas|3000|working level months|Inhalation| inhaled over 2 m at 1500 WL|4 (4 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-21-3|21|592|Other deterministic changes|Lower respiratory system|n/a|
2-5-21|Rn-FE-WL 3000,31-2 2/78|1| 77|Rn-222 gas|3000|working level months|Inhalation| inhaled over 2 m at 1500 WL|4 (4 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-21-4|21|627|Neoplasia malignant|Lower respiratory system|n/a|
2-5-21|Rn-FE-WL 3000,31-2 2/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|4 (4 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-21-1|21|518|Other deterministic changes|Lower respiratory system|n/a|
2-5-21|Rn-FE-WL 3000,31-2 2/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|4 (4 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-21-2|21|563|Other deterministic changes|Lower respiratory system|n/a|
2-5-21|Rn-FE-WL 3000,31-2 2/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|4 (4 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-21-3|21|592|Other deterministic changes|Lower respiratory system|n/a|
2-5-21|Rn-FE-WL 3000,31-2 2/78|2| 129|Fe mineral dust||unit code not relevant|Injection, intratracheal| mineral dust Fe intratracheal|4 (4 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-21-4|21|627|Neoplasia malignant|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-1|22|482|Other deterministic changes|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-2|22|482|Other deterministic changes|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-3|22|512|Other deterministic changes|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-4|22|557|Other deterministic changes|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-5|22|602|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-6|22|632|Other deterministic changes|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-7|22|647|Other deterministic changes|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-8|22|662|Other deterministic changes|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-9|22|662|Other deterministic changes|Lower respiratory system|n/a|
2-5-22|Rn-UR-WL 0,1-2 1/70|1| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-22-10|22|662|Other deterministic changes|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-1|23|22|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-2|23|22|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-3|23|22|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-4|23|22|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-5|23|302|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-6|23|358|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-7|23|449|Other deterministic changes|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-8|23|472|Other deterministic changes|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-9|23|507|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-10|23|507|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-11|23|507|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-12|23|549|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-13|23|567|Neoplasia malignant|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-14|23|612|Hyperplastic changes|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-15|23|622|Neoplasia malignant|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-16|23|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-17|23|622|Neoplasia malignant|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-18|23|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-19|23|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|1| 92|Rn-222 gas|9250|working level months|Inhalation| inhaled over 6 m at at 2500 WL|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-20|23|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-1|23|22|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-2|23|22|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-3|23|22|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-4|23|22|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-5|23|302|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-6|23|358|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-7|23|449|Other deterministic changes|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-8|23|472|Other deterministic changes|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-9|23|507|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-10|23|507|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-11|23|507|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-12|23|549|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-13|23|567|Neoplasia malignant|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-14|23|612|Hyperplastic changes|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-15|23|622|Neoplasia malignant|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-16|23|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-17|23|622|Neoplasia malignant|Lower respiratory system|n/a|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-18|23|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-19|23|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-5-23|Rn-UR-WL 9250,1-2 1/70|2| 92|Natural U ore||unit code not relevant|Inhalation| inhaled|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-23-20|23|622|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-1|24|90|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-2|24|243|Hyperplastic changes|Lower respiratory system|n/a|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-3|24|291|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-4|24|361|Neoplasia malignant|Other local manifestations and miscellaneus| metastatic|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-5|24|393|Hyperplastic changes|Lower respiratory system|n/a|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-6|24|427|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-7|24|465|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-8|24|499|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract| metastatic lung tumour,MPATH: 218 - neoplasm|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-9|24|509|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-10|24|536|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-11|24|538|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-12|24|601|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-13|24|618|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| metastatic,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-14|24|629|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-15|24|656|Neoplasia malignant|Lower respiratory system|n/a|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-16|24|657|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-17|24|662|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-5-24|Rn-Be-WL 1600,4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-18|24|663|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung| metastatic lung tumour,MPATH: 446 - squamous cell carcinoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-1|24|90|Neoplasia malignant|Bloodvessels among cardiovascular system| metastatic|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-2|24|243|Hyperplastic changes|Lower respiratory system|n/a|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-3|24|291|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-4|24|361|Neoplasia malignant|Other local manifestations and miscellaneus| metastatic|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-5|24|393|Hyperplastic changes|Lower respiratory system|n/a|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-6|24|427|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-7|24|465|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-8|24|499|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract| metastatic lung tumour,MPATH: 218 - neoplasm|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-9|24|509|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-10|24|536|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-11|24|538|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-12|24|601|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland| benign,MPATH: 268 - adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-13|24|618|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| metastatic,MPATH: 278 - follicular adenocarcinoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-14|24|629|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-15|24|656|Neoplasia malignant|Lower respiratory system|n/a|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-16|24|657|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system| benign,MPATH: 408 - soft tissue fibrosarcoma|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-17|24|662|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-5-24|Rn-Be-WL 1600,4/84|2| 377|beryllium|0.6|milligrams|Inhalation| inhaled|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-24-18|24|663|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung| metastatic lung tumour,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-1|25|398|Other deterministic changes|Whole body|n/a|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-2|25|399|Other deterministic changes|Lower respiratory system|n/a|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-3|25|399|Other deterministic changes|Lower respiratory system|n/a|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-4|25|417|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-5|25|422|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-6|25|423|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-7|25|457|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-8|25|487|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-9|25|490|Hyperplastic changes|Lower respiratory system|n/a|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-10|25|490|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-11|25|497|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|1| 92|Rn-222 gas|7800|working level months|Inhalation| inhaled at 2500 WL|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-12|25|497|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-1|25|398|Other deterministic changes|Whole body|n/a|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-2|25|399|Other deterministic changes|Lower respiratory system|n/a|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-3|25|399|Other deterministic changes|Lower respiratory system|n/a|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-4|25|417|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-5|25|422|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-6|25|423|Neoplasia malignant|Upper respiratory system,MA: 0000442 - upper respiratory tract|,MPATH: 218 - neoplasm|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-7|25|457|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-8|25|487|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-9|25|490|Hyperplastic changes|Lower respiratory system|n/a|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-10|25|490|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-11|25|497|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-25|Rn-CE-WL 7800,1-0 12/68|2| 92|cerium|1|milligrams|Inhalation| inhaled|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-25-12|25|497|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-1|26|7|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-2|26|7|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-3|26|7|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-4|26|77|Other deterministic changes|Lower respiratory system|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-5|26|305|Neoplasia benign|Lower respiratory system|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-6|26|393|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-7|26|396|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-8|26|473|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung| metastatic lung tumour,MPATH: 255 - adenoacanthoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-9|26|475|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-10|26|482|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 561 - adenosquamous carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-11|26|563|Neoplasia malignant|Lower respiratory system|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-12|26|587|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-13|26|594|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-14|26|607|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-15|26|623|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-16|26|657|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-17|26|671|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-18|26|681|Neoplasia malignant|Lower respiratory system| metastatic lung tumour|
2-5-26|Rn-GL-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-19|26|685|Neoplasia malignant|Lower respiratory system|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-1|26|7|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-2|26|7|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-3|26|7|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-4|26|77|Other deterministic changes|Lower respiratory system|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-5|26|305|Neoplasia benign|Lower respiratory system|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-6|26|393|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-7|26|396|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-8|26|473|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung| metastatic lung tumour,MPATH: 255 - adenoacanthoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-9|26|475|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-10|26|482|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 561 - adenosquamous carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-11|26|563|Neoplasia malignant|Lower respiratory system|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-12|26|587|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-13|26|594|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-14|26|607|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-15|26|623|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-16|26|657|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-17|26|671|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-18|26|681|Neoplasia malignant|Lower respiratory system| metastatic lung tumour|
2-5-26|Rn-GL-WL 1600,55 4/84|2| 377|glas fibers|20|milligrams|Inhalation| inhaled|19 (19 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-26-19|26|685|Neoplasia malignant|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-1|27|545|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-2|27|576|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-3|27|586|Other deterministic changes|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-4|27|632|Neoplasia benign|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-5|27|647|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-6|27|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-7|27|737|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-8|27|748|Hyperplastic changes|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-9|27|766|Neoplasia malignant|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-10|27|804|Neoplasia malignant|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-1|27|545|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-2|27|576|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-3|27|586|Other deterministic changes|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-4|27|632|Neoplasia benign|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-5|27|647|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-6|27|670|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-7|27|737|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-8|27|748|Hyperplastic changes|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-9|27|766|Neoplasia malignant|Lower respiratory system|n/a|
2-5-27|Rn-GL-WL 2240,37-8 4/79|2| 165|glas fibers|2|milligrams|Injection intrapleural| intrapleural|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-27-10|27|804|Neoplasia malignant|Lower respiratory system|n/a|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-1|28|244|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-2|28|302|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-3|28|360|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-4|28|365|Other deterministic changes|Lower respiratory system|n/a|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-5|28|396|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-6|28|417|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-7|28|450|Hyperplastic changes|Lower respiratory system|n/a|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-8|28|451|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-9|28|453|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-10|28|475|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-11|28|503|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-12|28|514|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-13|28|552|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-14|28|562|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-15|28|563|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-16|28|663|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-17|28|667|Neoplasia malignant|Lower respiratory system|n/a|
2-5-28|RN-QU-WL 1600,55 4/84|1| 92|Rn-222 gas|1600|working level months|Inhalation| inhaled over 2 m at 3000 WL|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-18|28|720|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-1|28|244|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-2|28|302|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-3|28|360|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-4|28|365|Other deterministic changes|Lower respiratory system|n/a|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-5|28|396|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-6|28|417|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-7|28|450|Hyperplastic changes|Lower respiratory system|n/a|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-8|28|451|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-9|28|453|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-10|28|475|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-11|28|503|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-12|28|514|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-13|28|552|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-14|28|562|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-15|28|563|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-16|28|663|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland| benign,MPATH: 278 - follicular adenocarcinoma|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-17|28|667|Neoplasia malignant|Lower respiratory system|n/a|
2-5-28|RN-QU-WL 1600,55 4/84|2| 377|quartz|10|milligrams|Inhalation| inhaled Quartz DQ|18 (18 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-28-18|28|720|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-1|29|635|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-2|29|732|Hyperplastic changes|Lower respiratory system|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-3|29|742|Neoplasia malignant|Lower respiratory system|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-4|29|747|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-5|29|752|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-6|29|762|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-7|29|769|Hyperplastic changes|Lower respiratory system|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-8|29|781|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-9|29|790|Hyperplastic changes|Lower respiratory system|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-10|29|843|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-1|29|635|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-2|29|732|Hyperplastic changes|Lower respiratory system|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-3|29|742|Neoplasia malignant|Lower respiratory system|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-4|29|747|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-5|29|752|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-6|29|762|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-7|29|769|Hyperplastic changes|Lower respiratory system|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-8|29|781|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-9|29|790|Hyperplastic changes|Lower respiratory system|n/a|
2-5-29|RN-QU-WL 2240,37-9 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| 12x intrapleural Quartz DQ|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-29-10|29|843|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-1|30|548|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-2|30|619|Other deterministic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-3|30|689|Other deterministic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-4|30|709|Neoplasia malignant|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-5|30|770|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-6|30|774|Hyperplastic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-7|30|777|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-8|30|797|Other deterministic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-9|30|799|Neoplasia malignant|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|1| 77|Rn-222 gas|2240|working level months|Inhalation| inhaled over 2.5 m at 1200 WL|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-10|30|839|Hyperplastic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-1|30|548|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-2|30|619|Other deterministic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-3|30|689|Other deterministic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-4|30|709|Neoplasia malignant|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-5|30|770|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-6|30|774|Hyperplastic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-7|30|777|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-8|30|797|Other deterministic changes|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-9|30|799|Neoplasia malignant|Lower respiratory system|n/a|
2-5-30|Rn-QUp-WL 2240,37-10 4/79|2| 165|quartz|2|milligrams|Injection intrapleural| intrapleural Quartz BRGM|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-5-30-10|30|839|Hyperplastic changes|Lower respiratory system|n/a|
		
